N	Concordance
1	espiratory distress syndrome through an interleukin-1 and tumor necrosis factor-
2	the amounts of interleukin-3 (IL-3) and interleukin-1 beta (IL-1 beta) released 
3	edical treatments include TNF alpha and interleukin-1 synthesis inhibitors or an
4	e interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine
5	e of platelet counts. Recombinant human interleukin-10 significantly suppressed 
6	parison to mild cases. Raised levels of interleukin-10 were more prevalent in ad
7	 of therapy consists of intraperitoneal interleukin-12 given weekly for 4 weeks.
8	domized to  receive either subcutaneous interleukin-12 (IL-12) twice weekly for 
9	he hepatic microvasculature: effects of interleukin-1alpha on metastasis and the
10	were shown to bear both a high-affinity interleukin-2 receptor (IL-2R) and a low
11	en label study.  Patients receive bolus interleukin-2 on days 1-5 and 8-12. The 
12	ponse induced by locoregional, low-dose interleukin-2 (IL-2) therapy. On day 0, 
13	the antitumor efficacy of intracavitary interleukin-2 plus  autologous lymphokin
14	mphocytes (TIL) expanded in recombinant interleukin-2 (rIL-2), and low-dose rIL-
15	     Evidence for an elevation in serum interleukin-2 and tumor necrosis factor-
16	erleukin-1 beta (IL-1 beta) and soluble interleukin-2 receptor (sIL-2R) were ass